^
    19h
    Potential evaluation of SULT1A3 as an early diagnostic marker for nasopharyngeal carcinoma: a study based on serum proteomics screening and ELISA validation. (PubMed, BMC Cancer)
    Through an integrated workflow combining proteomic screening, machine learning prioritization, and multi-stage ELISA validation, we identified SULT1A3 as a candidate serum-based biomarker for early detection of NPC. Preliminary findings suggest that SULT1A3 may have potential utility in clinical screening, though further validation in independent, multi‑center cohorts is required.
    Journal
    |
    CD8 (cluster of differentiation 8) • SULT1A3 (Sulfotransferase Family 1A Member 3) • FGL1 (Fibrinogen Like 1)
    1d
    Comprehensive multi-omics analysis reveals a fatty acid metabolism gene signature for prognostic assessment and immunotherapy in nasopharyngeal carcinoma, and identifies ABCC1 as a potential novel therapeutic target. (PubMed, Biol Direct)
    In summary, we established a novel fatty-acid-metabolism-related prognostic model for assessing the prognosis and potential immunotherapy response of NPC patients, as well as for characterizing the immunological features of the tumor microenvironment (TME). Furthermore, ABCC1 emerged as a promising prognostic biomarker associated with immunotherapeutic responsiveness in NPC, warranting further validation.
    Journal • Gene Signature • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • CYP4B1 (Cytochrome P450 Family 4 Subfamily B Member 1) • CD1D (CD1d Molecule)
    1d
    MALAT1 promotes autophagy via the mir-28-5p/IGF1R axis in nasopharyngeal carcinoma. (PubMed, Med Oncol)
    These pro-tumorigenic and pro-autophagic effects were consistently observed in vivo. In conclusion, MALAT1 promotes autophagy by sequestering miR-28-5p to upregulate IGF1R in NPC, providing a novel mechanistic insight and a potential therapeutic target.
    Journal
    |
    IGF1R (Insulin-like growth factor 1 receptor) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)
    1d
    Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. (PubMed, PLoS One)
    SLC44A4 overexpression also increased sensitivity to DNA-damaging agents, including temozolomide, doxorubicin, cisplatin, olaparib, and etoposide, while decreasing sensitivity to 5-fluorouracil. Together, these findings identify SLC44A4 as a potential tumor-suppressive factor in NPC and suggest that SLC44A4 may serve as a biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based therapies.
    Journal • PARP Biomarker
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • SLC44A4 (Solute Carrier Family 44 Member 4) • SLC4A4 (Solute carrier family 4 member 4)
    |
    Lynparza (olaparib) • cisplatin • 5-fluorouracil • temozolomide • doxorubicin hydrochloride • etoposide IV
    3d
    Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    docetaxel • SX-682
    3d
    BL-B01D1-303: A Phase III clinical trial comparing BL-B01D1 with physician-selected chemotherapy regimens (last line) in patients with recurrent or metastatic nasopharyngeal carcinoma who had previously received PD-1/PD-L1 monoclonal antibody therapy and failed at least two lines of chemotherapy. (clinicaltrials.gov)
    P3, N=386, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | -> Active, not recruiting | Phase classification: PN/A --> P3
    Enrollment closed • Phase classification
    |
    PD-L1 (Programmed death ligand 1)
    |
    gemcitabine • docetaxel • capecitabine • izalontamab brengitecan (BL-B01D1)
    4d
    Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=136, Completed, Shanghai Proton and Heavy Ion Center | Recruiting --> Completed
    Trial completion
    4d
    Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC (clinicaltrials.gov)
    P=N/A, N=900, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Dec 2028 --> Dec 2031 | Trial primary completion date: Dec 2028 --> Dec 2031
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    capecitabine
    5d
    Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P=N/A, N=178, Recruiting, Nanfang Hospital, Southern Medical University | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    5d
    Identification and validation of BLK and OSBPL10 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma through machine learning algorithms. (PubMed, Sci Rep)
    Immunohistochemical staining validation further confirmed that the protein expression levels of BLK and OSBPL10 are downregulated in NPC tissues compared with those in benign lesions, and their low expression is strongly associated with the poor prognosis of patients. In summary, these findings indicated that BLK and OSBPL10 may serve as candidate biomarkers for NPC diagnosis and prognosis, although further validation in independent cohorts is warranted.
    Journal
    |
    BLK (BLK proto-oncogene, Src family tyrosine kinase)
    6d
    CTV-MARGIN-NPC: Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=568, Not yet recruiting, Sun Yat-sen University
    New P3 trial • Head-to-Head
    |
    cisplatin